NasdaqCM - Nasdaq Real Time Price USD

FibroBiologics, Inc. (FBLG)

0.8250

-0.0475

(-5.44%)

As of 12:32:39 PM EDT. Market Open.

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growthHOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA,

GlobeNewswire 4 days ago

FBLG
-5.44%
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis…

By David Bautz, PhD NASDAQ:FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Preclinical Psoriasis Data Presented at SID Annual Meeting On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The poster entitled “Immunomodulatory Potential of Human Dermal Fibroblast Spheroids in Psoriasis Therapy”

Zacks Small Cap Research 22 days ago

FBLG
-5.44%
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Senior Research Scientist, Dr. Chuo Fang M.D., Ph.D., delivered a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting that took pl

GlobeNewswire 28 days ago

FBLG
-5.44%
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-

GlobeNewswire 29 days ago

FBLG
-5.44%
FibroBiologics Presents at the ThymUS 2025 Meeting

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Simon Gebremeskel, research scientist at FibroBiologics, is presenting a poster at the ThymUS 2025 Meeting taking place in Lihue, Kaua'i Hawaii from April 27 - Ma

GlobeNewswire last month

FBLG
-5.44%
FibroBiologics Presenting at the ThymUS 2025 Meeting

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Simon Gebremeskel, research scientist at FibroBiologics, is presenting a poster at the ThymUS 2025 Meeting taking place in Lihue, Kaua'i Hawaii from April 27 - Ma

GlobeNewswire last month

FBLG
-5.44%
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic d

GlobeNewswire 2 months ago

FBLG
-5.44%
OTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc., with David Bautz, PhD, Senior Analyst at Zacks SCR

NASDAQ:FBLG Hello and welcome to Virtual Investor Conferences. On behalf of the Life Sciences Investor Forum and our co-host, Zacks Small Cap Research, we're very pleased you joined us for our quarterly conference. Our next live presentation is from FibroBiologics. FibroBiologics is a cell therapy regenerative medicine company developing a pipeline of treatments and potential cures for chronic

Zacks Small Cap Research 2 months ago

FBLG
-5.44%
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technologyHOUSTON, April 08, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”) , a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the opening of a new laborat

GlobeNewswire 2 months ago

FBLG
-5.44%
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25…

By David Bautz, PhD NASDAQ:FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 FibroBiologics, Inc. (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers (DFUs), which we anticipate initiating in the second quarter of

Zacks Small Cap Research 2 months ago

FBLG
-5.44%
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a significant advancement in neurodegenerative disease research. Leveraging the well-established Cuprizone animal model, FibroBiologics has demonstrated that intravenous fibroblas

GlobeNewswire 2 months ago

FBLG
-5.44%
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing Preparations for Phase 1/2 clinical trial in Australia utilizing CYWC628 to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025 Cash and cash equivalents of approximately $14.0 million at December 31, 2024 HOUSTON, March 31, 2025 (GLOBE NEWSWIRE) -- FibroBi

GlobeNewswire 2 months ago

FBLG
-5.44%
FibroBiologics Announces 2025 Annual Meeting of Stockholders

HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination

GlobeNewswire 2 months ago

FBLG
-5.44%
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment

GlobeNewswire 2 months ago

FBLG
-5.44%
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download

GlobeNewswire 2 months ago

PDSB

TELIF

BPTSY
Life Sciences Investor Forum Agenda Announced for March 13th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4hnure6 It is recommended that inve

GlobeNewswire 2 months ago

NGENF

BPTSY

HMTXF
Uncovering Opportunities: 3 Penny Stocks With Market Caps Under $80M

As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly cautious about their next moves. In such a climate, penny stocks—often representing smaller or newer companies—can offer unique opportunities for those willing to explore beyond the blue-chip names. Despite being an outdated term, penny stocks remain relevant as they can combine value and growth potential, especially when backed by strong financials.

Simply Wall St. 3 months ago

FBLG
-5.44%

POCI

MLSS
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application wi

GlobeNewswire 3 months ago

FBLG
-5.44%
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcersHOUSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a leading, global provider of drug discovery, development, and manufacturing solutions, today announced the completion of FibroBiologics’ proprietary master cell bank that will support upcoming clinical trials. Manufactured

GlobeNewswire 3 months ago

FBLG
-5.44%
FBLG: Analyst Day Provides In-Depth Overview of Pipeline…

By David Bautz, PhD NASDAQ:FBLG READ THE FULL FBLG RESEARCH REPORT Business Update On February 12, 2025, Fibrobiologics, Inc. (NASDAQ:FBLG) held an Analyst Day and provided a comprehensive update on the company and its fibroblast-based development products. The presentation can be viewed here . The company is currently focused on a number of different therapeutic areas, including diabetic foot

Zacks Small Cap Research 3 months ago

FBLG
-5.44%

Performance Overview

Return	FBLG	S&P 500 (^GSPC)
YTD	-58.75%	+2.35%
1-Year	-88.51%	+10.78%
3-Year	-97.50%	+60.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

FibroBiologics, Inc. (FBLG)

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis…

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Presents at the ThymUS 2025 Meeting

FibroBiologics Presenting at the ThymUS 2025 Meeting

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

OTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc., with David Bautz, PhD, Senior Analyst at Zacks SCR

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25…

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

FibroBiologics Announces 2025 Annual Meeting of Stockholders

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for March 13th

Uncovering Opportunities: 3 Penny Stocks With Market Caps Under $80M

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

FBLG: Analyst Day Provides In-Depth Overview of Pipeline…

Performance Overview